Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs.

Wells AF, Parrino J, Mangan EK, Paccaly A, Lin Y, Xu C, Fan C, Graham NMH, van Hoogstraten H, Torri A.

Rheumatol Ther. 2019 May 14. doi: 10.1007/s40744-019-0157-3. [Epub ahead of print]

2.

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.

Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, Kameda H.

Arthritis Res Ther. 2019 Apr 16;21(1):99. doi: 10.1186/s13075-019-1887-x.

3.

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.

Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, Kameda H.

Arthritis Res Ther. 2019 Mar 20;21(1):79. doi: 10.1186/s13075-019-1856-4. Erratum in: Arthritis Res Ther. 2019 Apr 16;21(1):99.

4.

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.

Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM.

RMD Open. 2019 Feb 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798. eCollection 2019.

5.

Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale.

Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.

J Rheumatol. 2019 Mar 15. pii: jrheum.180904. doi: 10.3899/jrheum.180904. [Epub ahead of print]

6.

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.

Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, van Hoogstraten H, Mangan E, Carita P, Huynh TM.

Adv Ther. 2019 Apr;36(4):817-827. doi: 10.1007/s12325-019-00912-x. Epub 2019 Mar 12.

PMID:
30864105
7.

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group.

Pickles T, Alten R, Boers M, Bykerk V, Christensen J, Christensen R, van Hoogstraten H, Simon LS, Tam LS, Choy EH.

J Rheumatol. 2019 Feb 15. pii: jrheum.181054. doi: 10.3899/jrheum.181054. [Epub ahead of print]

PMID:
30770514
8.

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.

Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, Graham NMH, Liu N, Paccaly A, Wu R, Spindler A.

Rheumatology (Oxford). 2018 Dec 19. doi: 10.1093/rheumatology/key361. [Epub ahead of print]

9.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

10.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators.

Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121.

11.

Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.

Kivitz A, Baret-Cormel L, van Hoogstraten H, Wang S, Parrino J, Xu C, Stanislav M.

Rheumatol Ther. 2018 Jun;5(1):231-242. doi: 10.1007/s40744-017-0090-2. Epub 2017 Dec 5.

12.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.

RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017.

13.

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR.

Arthritis Rheumatol. 2017 Feb;69(2):277-290. doi: 10.1002/art.39944.

14.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.

Ann Rheum Dis. 2017 May;76(5):840-847. doi: 10.1136/annrheumdis-2016-210310. Epub 2016 Nov 17.

15.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.

Arthritis Res Ther. 2016 Sep 6;18:198. doi: 10.1186/s13075-016-1096-9.

16.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NM, Stahl N, Yancopoulos GD, Huizinga TW, van der Heijde D.

Arthritis Rheumatol. 2015 Jun;67(6):1424-37. doi: 10.1002/art.39093.

17.

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P.

Gastroenterology. 2014 Feb;146(2):392-400.e3.

PMID:
24512909
18.

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).

Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J.

Br J Dermatol. 2013 Jun;168(6):1325-34. doi: 10.1111/bjd.12404.

PMID:
23621698
19.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.

Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

PMID:
21910713
20.

High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis.

van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP.

J Hepatol. 2000 Oct;33(4):543-8.

PMID:
11059858
21.

Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.

van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR.

Am J Gastroenterol. 2000 Aug;95(8):2015-22.

PMID:
10950051
22.

The unusual patient with advanced renal insufficiency on ACE inhibitors.

van Hoogstraten HJ, van der Sluijs JP, van der Meulen J.

Nephrol Dial Transplant. 2000 Jan;15(1):130. No abstract available.

PMID:
10607788
23.

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.

van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW.

J Hepatol. 1999 Aug;31(2):256-62.

PMID:
10453938
24.

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study.

Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, van Berge-Henegouwen GP, ten Kate FJ, Hop WC, van der Hoek EW, Kerbert MJ, van Lijf HH, den Ouden JW, Smit AM, de Vries RA, van Zanten RA, Schalm SW.

J Hepatol. 1998 Nov;29(5):736-42.

PMID:
9833911
25.

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.

Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, Rijk MC, Smit AM, Zwertbroek R, Hop WC, van Berge Henegouwen GP, Schalm SW, van Buuren HR.

Aliment Pharmacol Ther. 1998 Oct;12(10):965-71.

26.

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.

van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, Kuiper H, Nix GA, Becx MC, Hoek AC, van Houte DP, Rijk MC, Salemans JM, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PH, Tan TG, Hop WC, ten Kate FJ, vanBerge-Henegouwen GP, Schalm SW, van Buuren HR.

J Hepatol. 1998 Sep;29(3):417-23.

PMID:
9764988

Supplemental Content

Loading ...
Support Center